Your AI-Trained Oncology Knowledge Connection!
November 17, 2020 - The PD-1 inhibitor tislelizumab was found to improve overall survival versus docetaxel in the second- or third-line treatment in patients with locally advanced or metastatic non–small cell lung cancer who progressed on previous platinum-based chemotherapy.
Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.
November 17, 2020 - The review of the biologics license application for the CAR T-cell product lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.
The identification of chromosomal rearrangements that result in oncogenic gene fusions ushered in the era of molecularly targeted therapies in oncology.
In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.
Matthew Lunning, DO, discussed other key considerations for choosing treatments, continuous vs fixed-duration therapies, and emerging agents for patients with relapsed/ refractory CLL and SLL.
Nilofer S. Azad, MD, highlights colorectal cancer treatment and how it has entered an era that is both exciting and challenging.
November 16, 2020 — The United Kingdom’s National Institute for Health and Care Excellence has recommended caplacizumab-yhdp with plasma exchange and immunosuppression for the treatment of an acute episode of acquired thrombotic thrombocytopenic purpura in adults and those aged 12 years and over who weigh at least 40 kg.
Weijing Sun, MD, FACP, discusses the great need for effective first-line treatment options in advanced/metastatic gastric and GEJ adenocarcinoma.
November 16, 2020 — The FDA has approved the PD-L1 IHC 22C3 pharmDx to aid in the identification of patients with triple-negative breast cancer who are eligible to receive the PD-1 inhibitor pembrolizumab.
November 16, 2020 - The combination of plinabulin and pegfilgrastim showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.
Hundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma.
The management of carcinoma of the cervix represents a remarkable dichotomy.
Nishitha M. Reddy, MD, MBBS, discusses the significance of the ECHELON-2 trial in peripheral T-cell lymphoma, the need for novel therapies for those with CD30-negative disease, and the excitement surrounding duvelisib in the relapsed/refractory setting.
November 15, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the fixed-dose combination of pertuzumab plus trastuzumab with hyaluronidase-zzxf for administration via subcutaneous injection in combination with intravenous chemotherapy in the treatment of patients with early and metastatic HER2-positive breast cancer
November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.
November 14, 2020 – Treatment with the novel intratumoral immuotherapy agent PVSRIPO resulted in an overall response rate of 33% among all patients with anti–PD-1 refractory melanoma.
November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.
November 13, 2020 - ALX148 showcased favorable safety and elicited objective responses when combined with trastuzumab, pembrolizumab, and multiagent chemotherapy regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma.
November 13, 2020 - The combination of bempegaldesleukin and the PD-1 inhibitor nivolumab elicited a confirmed best overall response rate of 53% in efficacy-evaluable patients with metastatic melanoma.
November 13, 2020 - The genetically modified herpes simplex-1 oncolytic RP2 demonstrated encouraging clinical activity and an acceptable safety profile in heavily pretreated patients with advanced solid tumors
November 13, 2020 - The FDA has granted an accelerated approval to pembrolizumab for use in combination with chemotherapy in the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 as determined by an FDA-approved test.
November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.
November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.
November 13, 2020 - The addition of plasmid IL-12 pembrolizumab resulted in durable responses, as well as several complete responses, in patients with advanced melanoma who were refractory to PD-1–directed therapy.
November 12, 2020 - The investigational PD-L1 inhibitor cosibelimab demonstrated durable and robust responses in patients with non–small cell lung cancer and cutaneous squamous cell carcinoma.
November 12, 2020 - The combination of CMP-001 intratumoral injection and pembrolizumab was found to reverse PD-1 blockade resistance and elicit durable systemic responses in patients with advanced melanoma.
November 12, 2020 - The first-in-class, next-generation, DuoBody-PD-L1×4-1BB bispecific antibody GEN1046 demonstrated promising early activity and an acceptable safety profile in in patients with advanced solid tumors.
November 12, 2020 - In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib with pembrolizumab is being evaluated in patients with advanced melanoma in a phase 1b/2 study.
Regulatory applications have been submitted to the FDA and the European Medicines Agency for subcutaneous daratumumab for use in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.
